Table II.
Clinical characteristics and treatment outcomes of patients grouped by RRM1 and ERCC1 status.
| Characteristics | RRM1 IHC (n=36) | P-value | ERCC1 IHC (n=37) | P-value | ||
|---|---|---|---|---|---|---|
|
|
|
|||||
| High n=16 (44%) | Low n=20 (56%) | High n=12 (32%) | Low n=25 (68%) | |||
| Median age, years (IQR) | 72 (69–79) | 73 (66–81) | 0.41a | 75 (66–79) | 71 (67–81) | 0.62a |
| Median follow-up, months (IQR) | 14 (10–35) | 19 (11–52) | 0.26a | 14 (9–24) | 20 (11–52) | 0.22a |
| Histology | ||||||
| Aberrant differentiation | 6 (38) | 5 (25) | 0.48b | 3 (25) | 8 (32) | 1.0b |
| Adjacent carcinoma in situ | 8 (50) | 8 (40) | 0.74b | 4 (16) | 10 (40) | 1.0b |
| Vascular invasion | 5 (31) | 2 (10) | 0.20b | 3 (25) | 4 (16) | 0.66b |
| Hydronephrosis | 7 (44) | 3 (15) | 0.073b | 5 (42) | 5 (20) | 0.24b |
| Clinical stage | ||||||
| II | 7 (44) | 12 (60) | 0.50b | 4 (33) | 16 (64) | 0.16b |
| III | 7 (44) | 7 (35) | 0.72b | 7 (58) | 7 (28) | 0.44b |
| IV | 2 (13) | 1 (5) | 0.069b | 1 (8) | 2 (7) | 0.37b |
| Chemotherapy | ||||||
| Neoadjuvant | 10 (63) | 8 (40) | 0.32b | 7 (58) | 11 (44) | 0.50b |
| Concomitant | 10 (63) | 14 (70) | 0.73b | 6 (50) | 19 (76) | 0.15b |
| Chemotherapy regimens | ||||||
| Gemcitabine | 7 (44) | 12 (60) | 0.50b | 7 (58) | 13 (52) | 1.0b |
| Platinum agents | 10 (63) | 9 (45) | 0.34b | 7 (58) | 12 (48) | 0.73b |
| Fluoropyrimidines | 7 (44) | 6 (30) | 0.49b | 5 (42) | 8 (32) | 0.72b |
| Paclitaxel | 6 (38) | 5 (25) | 0.48b | 6 (50) | 5 (20) | 0.12b |
| Complete response | 9 (56) | 19 (95) | 0.012b | 8 (67) | 21 (84) | 0.39b |
| Local recurrence | 2 (13) | 5 (25) | 1.0b | 0 | 7 (28) | 0.142b |
| Distant metastasis | 8 (50) | 3 (15) | 0.12b | 2 (17) | 8 (32) | 0.56b |
| Total deaths | 14 (88) | 8 (40) | 0.078b | 6 (50) | 14 (56) | 0.99b |
| Bladder cancer deaths | 9 (56) | 3 (15) | 0.057b | 3 (25) | 8 (32) | 0.96b |
a
Analysis of variance;
b
χ2 test. RRM1, ribonucleoside reductase subunit M1; ERCC1, excision repair cross-complementation group 1; IHC, immunohistochemistry; IQR, interquartile range.